Do patient co-morbidities impact when you prescribe oral jak inhibitors?

Great and pertinent question in our field. Autoimmunity doesn’t make me less likely to prescribe, actually more likely as there is plenty of case report and case series data on JAKi being used in a variety of autoimmune conditions. Certainly, dyslipidemia (think MACE), VTE risk, and malignancy risk ...

Not exactly the question you asked, but relevant recent study:

Russell et al., PMID 37247942

Yes